3rd Annual Oxford Global Biomarkers in Clinical Development Congress 2016 Manchester

  • Conference Call
  • The 3rd Annual Biomarkers in Clinical Development Congress will take place on the 25th & 26th February 2016 at the Manchester Central Convention Complex, Manchester, UK. The congress is co-​located with the 11th Annual Biomarkers Congress 2016.

    The Biomarkers in Clinical Development Congress will focus on the role of biomarkers in clinical development, clinical trials and clinical diagnostics. Industry leaders will discuss the role of NGS & genomic markers in clinical diagnostics & decision making. Hear the latest case studies on use of microRNA’s, CTCs and free circulating RNA & DNA as biomarkers in clinical diagnostics.

    Over the course of 2 days, our renowned speaker panel will discuss the following topics:

    • Overcoming challenges of clinical validation & translation
    • Surrogate endpoints: utilising biomarkers in clinical trials
    • Implementing biomarker data into clinical development strategies
    • Transforming clinical development through biomarker driven clinical trials design
    • Predictive biomarker discovery in proof-​of-​concept clinical studies
    • NGS for clinical testing & diagnostics
    • Case studies: mircoRNA’s, CTCs, circulating free DNA & exosomes
    • Biomarkers for non-​invasive diagnosis
    • The importance of liquid biopsies
    • Clinical effectiveness of diagnostic markers & screening of new markers

    Agenda

    Day 1 – Biomarker: Clinical Development & Clinical Trials

    • Overcoming challenges of clinical validation & translation
    • Surrogate endpoints: utilising biomarkers in clinical trials
    • Implementing biomarker data into clinical development strategies
    • Transforming clinical development through biomarker driven clinical trials design
    • Predictive biomarker discovery in proof-​of-​concept clinical studies

    Day 2 – Clinical Diagnostics, NGS & Genomic Markers

    • NGS for clinical testing & diagnostics
    • Case Studies: mircoRNA’s, CTCs, circulating free DNA & exosomes
    • Biomarkers for non-​invasive diagnosis
    • The importance of liquid biopsies
    • Clinical effectiveness of diagnostic markers & screening of new markers

    Advisory Board

    Our 2016 Conference Advisory Board Includes:

    • John Waterton – Translational Imaging, Biomedical Imaging Institute, The University of Manchester and co-​ordinator, IMI QuIC-​ConCePT consortium
    • Michael Merz – IMI SAFE-​T consortium, Novartis Institutes for BioMedical Research
    • Lakshmi Amaravadi – Translational Sciences, BiogenIdec
    • Robert Nelson – Bioanalytical Assay Laboratory, NovImmune SA
    • Sally Mountain – Correlative Science, Novartis
    • Peter Groenen – Translational Science, Actelion Pharmaceuticals Ltd.
    • Richardus Vonk – Research and Clinical Sciences Statistics, Bayer Pharma AG
    • Andreas Popp – Pathologist, Abbvie
    • David Henderson – Bayer Pharma AG
    • Matthias Hackl – TAmiRNA GmbH
    • Mads Almose Røpke – LEO Pharma A/​S
    starting: ending: 26.02.2016 Location: , Category:

    Timeline

    Conference START 26.02.2016 END

    All deadlines have expired!

    This conference has no more open deadlines. There may be successive conferences coming up you may by interested in.

    Please check our conference list and search...

    Conference Facts

    Location , Address Manchester Central Category Organiser More Info Conference Website

    Further interesting Conferences

    Currently we have no similar events listed. Please check our website regulary, subscribe to our RSS-Feed or follow us on twitter for new listings.